Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device

Catheter Precision, a subsidiary of Flyte Aviation (NYSE American: VJET), published a peer-reviewed study in The Journal of Interventional Cardiology demonstrating that its LockeT suture retention device outperforms Abbott's Perclose vascular closure device. The 172-patient study showed LockeT achieved 1.2% access-site complications versus 9.3% for Perclose, with zero device failures compared to 4.7% for Perclose, while maintaining equivalent efficiency in hemostasis and same-day discharge rates.

10/22/2026, 4:54 PM • GlobeNewswire

Abbott: 3 Key Takeaways for Long-Term Investors

Abbott announced plans to spin off its nutrition business into an independent public company, focusing on higher-margin medical technologies and diagnostics. The company reported 7% year-over-year comparable sales growth in Q3 2026, with cancer diagnostics sales up 14% driven by Cologuard and new blood-based colorectal cancer screening tests. Pulsed field ablation technology is accelerating growth in electrophysiology, positioning Abbott for accelerated growth beyond historical rates.

10/21/2026, 4:15 PM • The Motley Fool

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale

The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.

10/21/2026, 5:00 AM • GlobeNewswire

Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.

With the Federal Reserve likely to maintain or raise interest rates through the end of 2026, dividend stocks like AbbVie are positioned to perform well. AbbVie, a pharmaceutical company with over 50 years of dividend increases, offers resilience in a high-rate environment due to its strong balance sheet, fixed-rate debt, and non-rate-sensitive business model.

10/20/2026, 11:45 AM • The Motley Fool

3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case.

Three Wall Street analysts have $500 price targets for Intuitive Surgical, citing strong growth in robot-assisted surgery procedures and the rollout of the da Vinci 5 platform. The company benefits from a recurring revenue model through instruments and accessories, with procedures growing 15% year-over-year. However, the stock's high P/E ratio of ~49 leaves limited room for disappointment.

10/19/2026, 9:30 AM • The Motley Fool

Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.

Ken Griffin's Citadel significantly increased positions in healthcare stocks during Q2, boosting AbbVie by 546%, Abbott Laboratories by 349%, and Eli Lilly by 291%. The moves suggest Griffin is seeking defensive, dividend-yielding stocks amid anticipated market volatility. AbbVie, a Dividend King with 54 consecutive years of dividend increases, is highlighted as a strong buy with attractive valuation and solid earnings growth.

10/18/2026, 8:15 AM • The Motley Fool

Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle

AbbVie is positioned as a reliable dividend stock that avoids high-yield trap characteristics. With 54 consecutive years of dividend increases, strong free cash flow generation, fixed-rate debt, and blockbuster drugs Skyrizi and Rinvoq generating over $7.5 billion quarterly, AbbVie maintains Dividend King status regardless of interest rate cycles. The company's robust pipeline of 90 clinical programs provides future revenue stability.

10/17/2026, 4:44 AM • The Motley Fool

Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight

The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure.

10/14/2026, 1:00 PM • GlobeNewswire

Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell

The article recommends two Dividend King healthcare stocks for passive income: Abbott Laboratories and Johnson & Johnson. Both companies have demonstrated 50+ years of consecutive dividend increases, strong free cash flow, diversified business portfolios, and solid growth prospects. Abbott offers a 2.5% dividend yield with innovative products like the Libre Duo glucose monitor, while J&J pays a 2% yield and is positioned to reach $100 billion in annual revenue with a strong oncology pipeline.

10/12/2026, 6:10 PM • The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

10/12/2026, 2:40 PM • The Motley Fool

Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

Freenome announced improved validation data for its updated SimpleScreen CRC blood-based colorectal cancer screening test, demonstrating 18.2% sensitivity for advanced precancerous lesions (up from 13.7%) and 80.4% sensitivity for colorectal cancer detection at 90% specificity. The FDA-approved test, commercialized by partner Abbott Cancer Diagnostics, will be presented at ACG 2026 Annual Meeting in Nashville.

10/11/2026, 1:00 PM • GlobeNewswire

History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.

Abbott Laboratories is positioned for significant growth potential, with analyst projections suggesting the stock could reach approximately $210 per share by 2036 based on conservative 8% annual earnings growth. The healthcare company's strong track record includes a 9.7% compound annual earnings-per-share growth rate over the past decade, bolstered by strategic acquisitions. Abbott's status as a Dividend King with 54 consecutive years of dividend increases, combined with a 2.5% dividend yield, makes it an attractive option for income-focused investors seeking defensive holdings with upside potential.

10/10/2026, 2:15 PM • The Motley Fool

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens

Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments.

10/09/2026, 10:30 AM • The Motley Fool

China Adult Feeding Tubes and Formula Market Outlook to 2033 - Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities

ResearchAndMarkets.com released a comprehensive market report on China's adult feeding tubes and formula market through 2033, providing revenue, volume, and pricing forecasts. The report analyzes two main segments (Adult Feeding Tubes and Adult Feeding Formula) and includes competitive landscape data with 2025 company share information for key market participants.

10/09/2026, 4:57 AM • GlobeNewswire

Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight

The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.

10/06/2026, 1:00 PM • GlobeNewswire